Last reviewed · How we verify
Cyclophosphamid
Cyclophosphamid is a Small molecule drug developed by Zhejiang University. It is currently FDA-approved for Acute lymphoid leukemia, disease, Acute monocytic leukemia, Acute myelogenous leukemia. Also known as: Anti-thymocyte globulin, Cyclophosphamide, huanlinxianan, Indoxan.
Cyclophosphamide is a small molecule medication used as chemotherapy to treat various cancers, including breast cancer, lymphoma, multiple myeloma, leukemia, ovarian cancer, small cell lung cancer, neuroblastoma, and sarcoma. It is also used to suppress the immune system in conditions such as nephrotic syndrome, ANCA-associated vasculitis, and following organ transplantation.
At a glance
| Generic name | Cyclophosphamid |
|---|---|
| Also known as | Anti-thymocyte globulin, Cyclophosphamide, huanlinxianan, Indoxan, CTX |
| Sponsor | Zhejiang University |
| Target | Cytochrome P450 3A4 |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | FDA-approved |
Approved indications
- Acute lymphoid leukemia, disease
- Acute monocytic leukemia
- Acute myelogenous leukemia
- Adenocarcinoma of the ovary
- Burkitt's lymphoma
- Carcinoma of breast
- Chronic lymphoid leukemia, disease
- Chronic myeloid leukemia
- Histiocytic lymphoma
- Hodgkin's disease
- Malignant lymphoma
- Mixedcell type lymphoma
- Multiple myeloma
- Mycosis fungoides
- Neuroblastoma
- Retinoblastoma
- Systemic AL amyloidosis
- Treatment prior to tumor-specific T-cell infusion therapy
Common side effects
- Neutropenia
- Febrile neutropenia
- Fever
- Alopecia
- Nausea
- Vomiting
- Diarrhea
- Myelosuppression
- Fatigue
- Headache
- Malaise
- Pain
Serious adverse events
- Cardiac arrest
- Cardiac failure
- Cardiomyopathy
- Myocardial infarction
- Hemorrhagic cystitis
- Renal failure
- Sepsis
- Acute leukemia
- Bladder cancer
- Veno-occlusive liver disease
Key clinical trials
- Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (PHASE3)
- Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma (PHASE3)
- Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma (PHASE2)
- Pilot Trial of Allogeneic Blood or Marrow Transplantation for Primary Immunodeficiencies (PHASE2)
- Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia (PHASE2)
- Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL (PHASE1, PHASE2)
- A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032) (PHASE3)
- A Study to Investigate Blinatumomab in Combination With Chemotherapy in Patients With Newly Diagnosed B-Lymphoblastic Leukemia (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Cyclophosphamid CI brief — competitive landscape report
- Cyclophosphamid updates RSS · CI watch RSS
- Zhejiang University portfolio CI
Frequently asked questions about Cyclophosphamid
What is Cyclophosphamid?
What is Cyclophosphamid used for?
Who makes Cyclophosphamid?
Is Cyclophosphamid also known as anything else?
What development phase is Cyclophosphamid in?
What are the side effects of Cyclophosphamid?
What does Cyclophosphamid target?
Related
- Target: All drugs targeting Cytochrome P450 3A4
- Manufacturer: Zhejiang University — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Acute lymphoid leukemia, disease
- Indication: Drugs for Acute monocytic leukemia
- Indication: Drugs for Acute myelogenous leukemia
- Also known as: Anti-thymocyte globulin, Cyclophosphamide, huanlinxianan, Indoxan, CTX
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing